A public map of trial deserts to steer where new sites open
Combine cancer incidence with the location of open trials to show which regions have many patients but no trial within an hour's drive. Sponsors and funders would use it to decide where to put sites.
An open, regularly updated geospatial dataset joins registry incidence (by county or district) with trial site locations and recruitment status from ClinicalTrials.gov and other registries, producing an index of trial access by disease, with travel-time isochrones and demographic overlays. Sponsors are asked to justify site selection against the map in diversity plans.
- Trials do not represent the people who get cancer · Older, Black, Hispanic, Asian, rural, poor and multimorbid patients are under-represented, so results may not apply to them.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
- Data silos · Records, scans, genomes and outcomes sit in separate systems that cannot talk. Every patient's experience is lost to the next.
Pages like this
not linked directly; found by shared links- IdeaSet trial enrolment targets from who actually gets the disease, and publish progress live
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results), ClinicalTrials.gov, Trials do not represent the people who get cancer.
- IdeaMake a population cancer registry a condition of every cancer aid programme
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results), International Agency for Research on Cancer (IARC / WHO), Data silos.
- IdeaAn open global model of cancer workforce supply and demand by country
Shares GLOBOCAN / Global Cancer Observatory, International Agency for Research on Cancer (IARC / WHO), Data silos.
- IdeaOpen-source cancer registry-in-a-box for low-resource settings
Shares GLOBOCAN / Global Cancer Observatory, International Agency for Research on Cancer (IARC / WHO), Data silos.
- JournalCA: A Cancer Journal for Clinicians
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results).
- IdeaA live 'seats available' feed for trial slots, like airline inventory
Shares ClinicalTrials.gov, Trials enrol too few, too slowly, Data silos.
- IdeaDefault-inclusive eligibility: sponsors must justify every exclusion criterion
Shares ClinicalTrials.gov, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
- IdeaA public tracker of how long each country takes to adopt new evidence
Shares GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results).